U.S. Markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.45
    +0.17 (+0.76%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    48,371.05
    -6,755.18 (-12.25%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Intellia NTLA and partner Regeneron REGN announced that the FDA has granted Orphan Drug designation (“ODD”) to their CRISPR genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis.

The ODD is granted by the FDA to those candidates that are being developed to treat, diagnose or prevent a rare disease or condition. ODD makes the sponsor eligible to receive seven years of market exclusivity following potential approval and tax credit for qualified clinical studies.

NTLA-2001 has already received a similar designation from the European Commission earlier this year in March.

Shares of Intellia gained 3.9% on Oct 21 following the news. In fact, the stock has rallied 146.7% so far this year against the industry’s 10.1% decline.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

We inform investors that ATTR amyloidosis is a fatal indication that causes the liver to produce structurally abnormal transthyretin (TTR) protein that has a propensity to misfold. This causes serious complications in multiple tissues including heart failure and nerve damage.

NTLA-2001 is currently being evaluated in a phase I study in adults with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).

In June 2021, Intellia and Regeneron announced interim positive data from the above-mentioned phase I study. Data from the study demonstrated that treatment with a single dose of NTLA-2001 (0.3 mg/kg) has the potential to halt and reverse the devastating complications of ATTR amyloidosis. Patients treated with the therapy NTLA-2001 exhibited a mean reduction of 87% in serum TTR levels, with a maximum 96% serum TTR reduction by day 28, and showed a dose-dependent response. Usually, the standard of care for ATTRv-PN generates TTR reductions of approximately 80%.

We remind investors that NTLA-2001 is one of the many CRISPR candidates being developed by the company with Regeneron. Intellia’s partnership with Regeneron is part of a collaboration agreement aimed at developing CRISPR/Cas9-based treatments across multiple indications. Currently, both the companies are also co-developing potential CRISPR/Cas9-based therapies for hemophilia A and B.

CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. Therapies using the CRISPR technology can selectively delete, modify or correct a disease-causing abnormality in a specific deoxyribonucleic acid segment.

Competition is stiff in this space from companies like Editas Medicine EDIT and CRISPR Therapeutics CRSP, which are also utilizing the CRISPR/Cas9 gene-editing technology to develop their respective candidates for addressing various ailments.

Intellia Therapeutics, Inc. Price

Intellia Therapeutics, Inc. Price
Intellia Therapeutics, Inc. Price

Intellia Therapeutics, Inc. price | Intellia Therapeutics, Inc. Quote

Zacks Rank

Intellia currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report

Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report

CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research